Scinovex
letterTop 1% cited

A randomized double-blind phase III study of nimorazole as a hypoxic radiosensitizer of primary radiotherapy in supraglottic larynx and pharynx carcinoma. Results of the Danish Head and Neck Cancer Study (DAHANCA) Protocol 5-85

Radiotherapy and Oncology · 1998 · Vol. 46(2) · pp. 135–146
Jens OvergaardHanne Sand HansenMarie OvergaardLars BastholtAnne BerthelsenLena SpechtBirgit LindeløvKarsten Juhl Jørgensen
Head and Neck Cancer StudiesLung Cancer Diagnosis and TreatmentLung Cancer Treatments and MutationsMedicineHead and neck cancerLarynxChemoradiotherapyRadiation therapyInternal medicinePharynxCarcinomaPlaceboRadiosensitizer

MeSH terms

AdultAgedAged, 80 and overCombined Modality TherapyDouble-Blind MethodFemaleHumansLaryngeal NeoplasmsMaleMiddle AgedNimorazolePharyngeal NeoplasmsPlacebosRadiation-Sensitizing AgentsCell Hypoxia
Citations
563
FWCI
14.65
field-weighted impact
References
44
Percentile
100%
vs. same field & year
Citations per year
Citation Network

How this paper connects to the literature. Drag to explore, click any node to open that paper.